OREANDA-NEWS. On 31 March 2008 was announced, that Mildronats®, the original product of Grindeks JSC, leader in the group of medicaments for cardiovascular system treatment, which, at Made in Latvia Contest, in the category of products manufactured by large-scale enterprises producing inedible products, for the fifth time had been recognized as a product the most exportable from Latvia.

In 2007 the highest turnover was reached by Mildronats® which constituted 73 % of the total amount of sales of Grindeks’s final dosage forms, reaching the turnover of 34.8 million lats, which was by 6.2 million lats or 22% more than in 2006. Mildronats® was being exported by Grindeks to Lithuania, Russia, Kazakhstan, Ukraine, Byelorussia, Moldova, Georgia, Azerbaijan, Tadjikistan, Kirghizia and Uzbekistan. In 2007 Mildronвts® had been started to export also to Armenia.

“The exportability of Mildronats® can only be increasing in the future”, - affirms Jвnis Romanovskis, Chairman of the Management Board of Grindeks, “since the registration of this product has been started in such wide and perspective markets as China and Turkey.”

163 products, manufactured by 52 companies, having been exported to a total of 44 countries in 2007, most to Lithuania, Estonia, Russia, Ukraine and Kazakhstan, at the above mentioned Contest were nominated for the title of the most exportable finished product of the year 2007. The criterion to estimate an exportability of nominated products was their export volume in 2007 calculated in lats.

Made in Latvia Contest was held for the tenth time within ten years by GS1 Latvija, National Organization for Automatic Bar Code Identification, and the Office of Latvian Chamber of Commerce and Industry. The Contest is aimed to promote the export of Latvian goods, to develop the international bar-code system GS1 in Latvia, as well as to create a positive image of Latvia both in Latvia and foreign countries.

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are research, development and manufacturing of brand products, generics and active pharmaceutical ingredients. Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of Grindeks’s products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein.

Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia as well as ten representative offices. Products of the company are exported to more than 40 countries. Main markets are the Baltic States, Russia and CIS countries, Japan, USA. Grindeks shares are listed in the Official List of Riga Stock Exchange.